Company Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products.
Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.
The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector.
It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Nov 17, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 135 |
| CEO | John H. Tucker |
Contact Details
Address: 25 Burlington Mall Road, Suite 203 Burlington, Massachusetts 01803 United States | |
| Phone | 617-517-0730 |
| Website | scpharmaceuticals.com |
Stock Details
| Ticker Symbol | SCPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001604950 |
| CUSIP Number | 810648105 |
| ISIN Number | US8106481059 |
| Employer ID | 46-5184075 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John H. Tucker | President, Chief Executive Officer, Principal Executive Officer and Director |
| Rachael Nokes | Chief Financial Officer and Principal Accounting Officer |
| Michael D. Hassman | Senior Vice President of Technical Operations |
| Katherine Taudvin | Vice President of Corporate Affairs and Human Resources |
| Dr. John Mohr Pharm.D. | Senior Vice President of Clinical Development and Medical Affairs |
| Steve Parsons | Senior Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 22, 2024 | EFFECT | Notice of Effectiveness |
| Mar 22, 2024 | 424B5 | Filing |
| Mar 18, 2024 | UPLOAD | Filing |
| Mar 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 13, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |